TABLE 1.
Baseline characteristics of the patient cohort
| Parameter | Mean value |
|---|---|
| Age (years) | 67.3 ± 10.3 |
| Male sex (n) | 92 (75.4%) |
| Body height (cm) | 162.5 ± 7.6 |
| Body weight (kg) | 65.8 ± 12.1 |
| Body mass index (kg/m2) | 24.8 ± 4.1 |
| Systolic blood pressure (mmHg) | 121 ± 17 |
| Diastolic blood pressure (mmHg) | 71 ± 11 |
| Heart rate (bpm) | 80 ± 15 |
| Heart failure duration (years) | 4.5 ± 3.2 |
| Diabetes mellitus (n) | 54 (44.3%) |
| Hypertension (n) | 55 (45.1%) |
| Dyslipidemia (n) | 46 (37.7%) |
| Coronary artery disease (n) | 45 (36.9%) |
| Chronic kidney disease (n) | 52 (42.6%) |
| Atrial fibrillation (n) | 41 (33.6%) |
| Creatinine (mg/dL) | 1.38 ± 1.24 |
| eGFR (mL/min/1.73m2) | 62.0 ± 22.5 |
| Sodium (meq/L) | 144 ± 34 |
| Potassium (meq/L) | 4.2 ± 0.6 |
| Blood NT‐proBNP (pg/mL) | 2856.7 ± 3999.8 |
| Urine creatinine (mg/dL) | 73.9 ± 51.4 |
| Urine NT‐proBNP (pg/mL) | 1210.7 ± 6122.8 |
| Urine NT‐proBNP/creatinine ratio (pg/μgCr) | 1.89 ± 8.71 |
| Left atrial diameter (cm) | 4.3 ± 0.9 |
| Average mitral E/e′ | 12.6 ± 5.5 |
| Ejection fraction (%) | 36.2 ± 9.2 |
| Medications taken (n, patients; %) | |
| ACEI | 7 (5.7%) |
| ARB | 84 (68.9%) |
| ARNI | 25 (20.5%) |
| MRA | 48 (39.3%) |
| Beta blockers | 87 (71.3%) |
| Diuretics | 66 (54.1%) |
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal pro b‐type natriuretic peptide.
Total N, 122. Data are presented as the mean ± standard deviation.